Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJul 10, 2026
DataAggregated Company Financials
Companies182
  • 7D1.8%
  • 3M17.9%
  • 1Y14.4%
  • YTD16.5%

Over the last 7 days, the Pharma industry has remained flat, although notably Sun Pharmaceutical Industries gained 3.6%. As for the the longer term, the industry is up 13% over the past 12 months. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 10 Jul 2026₹23.8t₹4.5t₹643.1b30.1x37x5.3x
Sun, 07 Jun 2026₹22.1t₹4.5t₹643.0b28.9x34.3x4.9x
Tue, 05 May 2026₹21.3t₹4.4t₹619.9b29.3x34.3x4.9x
Thu, 02 Apr 2026₹19.8t₹4.3t₹621.4b25.8x31.8x4.6x
Sat, 28 Feb 2026₹20.5t₹4.3t₹621.1b26.2x32.9x4.7x
Mon, 26 Jan 2026₹19.5t₹4.2t₹605.2b29.1x32.2x4.6x
Wed, 24 Dec 2025₹20.6t₹4.2t₹614.5b29.4x33.5x4.9x
Fri, 21 Nov 2025₹20.4t₹4.2t₹611.2b29.5x33.4x4.9x
Sun, 19 Oct 2025₹20.3t₹4.1t₹589.9b30.6x34.4x5x
Tue, 16 Sep 2025₹20.5t₹4.1t₹589.1b31.7x34.8x5x
Thu, 14 Aug 2025₹20.2t₹4.1t₹588.7b30.6x34.4x5x
Sat, 12 Jul 2025₹20.4t₹4.0t₹594.1b32.6x34.3x5.1x
Mon, 09 Jun 2025₹20.2t₹4.0t₹595.3b32x33.9x5.1x
Wed, 07 May 2025₹19.4t₹3.9t₹563.0b28.9x34.4x5x
Fri, 04 Apr 2025₹19.6t₹3.9t₹559.4b29.6x35.1x5x
Sun, 02 Mar 2025₹18.0t₹3.9t₹559.4b26.2x32.3x4.6x
Tue, 28 Jan 2025₹19.4t₹3.8t₹531.6b30.4x36.5x5.1x
Thu, 26 Dec 2024₹20.8t₹3.8t₹526.7b34.8x39.4x5.5x
Sat, 23 Nov 2024₹20.3t₹3.8t₹526.7b31.7x38.5x5.3x
Mon, 21 Oct 2024₹21.4t₹3.7t₹492.6b40.1x43.4x5.7x
Wed, 18 Sep 2024₹21.6t₹3.7t₹492.6b41.8x44x5.8x
Fri, 16 Aug 2024₹20.2t₹3.8t₹492.2b35.6x41.1x5.4x
Sun, 14 Jul 2024₹18.6t₹3.6t₹449.9b35x41.4x5.2x
Tue, 11 Jun 2024₹17.4t₹3.6t₹448.1b33x38.8x4.9x
Thu, 09 May 2024₹16.9t₹3.5t₹423.6b33.8x39.8x4.8x
Sat, 06 Apr 2024₹17.2t₹3.5t₹418.9b33.6x41.1x4.9x
Mon, 04 Mar 2024₹17.0t₹3.5t₹418.7b33.7x40.6x4.9x
Wed, 31 Jan 2024₹15.8t₹3.4t₹396.1b34.6x39.9x4.7x
Fri, 29 Dec 2023₹14.9t₹3.4t₹395.2b32.5x37.7x4.4x
Sun, 26 Nov 2023₹14.0t₹3.4t₹395.1b31x35.6x4.2x
Tue, 24 Oct 2023₹12.8t₹3.3t₹368.0b29.1x34.9x3.9x
Thu, 21 Sep 2023₹13.2t₹3.3t₹369.5b29.9x35.7x4x
Sat, 19 Aug 2023₹13.0t₹3.3t₹367.1b29.1x35.5x4x
Mon, 17 Jul 2023₹11.9t₹3.2t₹342.6b26.3x34.8x3.8x
Price to Earnings Ratio

34.8x


Total Market Cap: ₹11.9tTotal Earnings: ₹342.6bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-0.87%
Healthcare1.16%
Pharma1.83%
Pharma1.83%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.94k3.6%
+₹162.4b		16.6%PE40.5x
500420 Torrent Pharmaceuticals₹4.90k5.0%
+₹79.2b		46.6%PE76.6x
ZYDUSLIFE Zydus Lifesciences₹1.16k5.4%
+₹59.1b		19.1%PE22.9x
500257 Lupin₹2.50k4.3%
+₹47.6b		32.0%PE21.5x
500488 Abbott India₹26.76k4.1%
+₹22.1b		-22.7%PE36.6x

Latest News

500257
₹2,502.90
Lupin
7D
4.3%
1Y
32.0%
ACUTAAS
₹3,458.80
Acutaas Chemicals
7D
-6.3%
1Y
205.0%
SUNPHARMA
₹1,938.70
Sun Pharmaceutical Industries
7D
3.6%
1Y
16.6%
Analysis Article • Jul 09

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results: Here's What Analysts Are Forecasting For This Year

The full-year results for Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) were released last week, making it a...
ZYDUSLIFE
₹1,159.00
Zydus Lifesciences
7D
5.4%
1Y
19.1%
New Narrative • Jul 08

Specialty And Rare Disease Expansion Will Reshape This Diversified Healthcare Leader’s Long-Term Potential

Catalysts About Zydus Lifesciences Zydus Lifesciences is a diversified healthcare company with businesses across pharmaceuticals, specialty and rare disease therapies, consumer wellness and medical devices. What are the underlying business or industry changes driving this perspective?
GLENMARK
₹2,267.20
Glenmark Pharmaceuticals
7D
3.2%
1Y
19.1%
Narrative Update • Jul 07

GLENMARK: Updated US Portfolio And Margin Assumptions Will Shape Future Earnings

Analysts have raised their fair value estimate for Glenmark Pharmaceuticals from about ₹1,531.86 to roughly ₹2,116.59, citing updated assumptions on revenue growth, profit margin, discount rate and future P/E that they believe better reflect the stock's current risk and earnings profile. What’s in the News for Glenmark Pharmaceuticals Glenmark Pharmaceuticals held an Analyst and Investor Day, providing the market with an updated view of its business priorities, capital allocation plans, and assumptions that can influence how investors assess the stock.
SUPRIYA
₹874.90
Supriya Lifescience
7D
-12.1%
1Y
26.2%
WOCKPHARMA
₹1,831.30
Wockhardt
7D
-6.1%
1Y
7.9%
500124
₹1,269.80
Dr. Reddy's Laboratories
7D
-5.7%
1Y
0.8%
LAURUSLABS
₹1,507.40
Laurus Labs
7D
-1.3%
1Y
90.0%
Narrative Update • Jul 02

LAURUSLABS: Currency And Execution Risks Will Continue To Restrain Margin Upside

Analysts have revised their fair value estimate for Laurus Labs to ₹606.49 from ₹543.09, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple. What’s in the News for Laurus Labs Laurus Labs has scheduled a board meeting on April 30, 2026, at 14:00 IST to consider audited financial results for the quarter and year ended March 31, 2026, along with several corporate actions.
MANKIND
₹2,532.00
Mankind Pharma
7D
1.8%
1Y
-0.5%
512529
₹280.85
Viyash Scientific
7D
-3.9%
1Y
49.4%
Narrative Update • Jun 26

512529: Higher Margin Outlook And Governance Changes Will Support Bullish Repricing

The analyst fair value price target for Viyash Scientific has been raised from ₹267 to ₹300 as analysts factor in updated assumptions that combine a lower modelled revenue growth rate of 13.37%, a higher profit margin estimate of 18.73%, and a slightly reduced future P/E of 24.31x. What’s in the News for Viyash Scientific Viyash Scientific plans an Analyst and Investor Day, giving the market an opportunity to hear updated management commentary and business priorities.
CIPLA
₹1,441.30
Cipla
7D
-1.0%
1Y
-2.5%
500420
₹4,896.65
Torrent Pharmaceuticals
7D
5.0%
1Y
46.6%
Narrative Update • Jun 25

500420: Dividend Payouts And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their fair value estimate for Torrent Pharmaceuticals steady at about ₹4,878.79 per share, citing unchanged assumptions for revenue growth, profit margins, discount rate, and future P/E multiple. What's in the News for Torrent Pharmaceuticals At its AGM on 23 June 2026, Torrent Pharmaceuticals declared a final dividend of ₹9.00 per equity share of face value ₹5.00 for the financial year ended 31 March 2026.
EMCURE
₹1,809.50
Emcure Pharmaceuticals
7D
-2.5%
1Y
41.0%
Narrative Update • Jun 23

EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook

Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.
506943
₹2,440.95
J. B. Chemicals & Pharmaceuticals
7D
5.3%
1Y
51.4%
500488
₹26,763.45
Abbott India
7D
4.1%
1Y
-22.7%